Cblb-based Drugs Against Sepsis and Inflammation

Abstract Septicemia poses a major health care challenge. Modern therapies requiring suppression of patients' immune systems, a growing numbers of elderly people in the population, and the emergence of drug-resistant bacteria, have increased the prevalenceand severity of the disease over the past few decades. Current treatments rely on drugs that do not significant reduce morbidity and mortality. We have discovered that the E3 ubiquitin ligase Cblb can be administered to mice to dramatically curb acute systemic inflammation and lung inflammatory injury in response to the endotoxin of Gram-negative bacteria. We have also delineated the fundamental signaling pathways at which Cblb acts in human cells and showed that its therapeutic benefit is dependent on itsE ligase activity. Thus, we now have the knowledge to exploit the therapeutic potential of Cblb as a drug. CellBiologics Inc. proposes to utilize a novel anti-inflammatory cell signaling pathway, i.e., a potential therapeutic human protein, Cblb, that can